Identification of urinary peptide biomarkers associated with rheumatoid arthritis

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Stalmach, Angelique ^a   Johnsson, Hanna ^b   McInnes, Iain B ^c   Husi, Holger ^a   Klein, Julie ^d   Dakna, Mohammed ^d   Mullen, William ^a   Mischak, Harald ^a,d   Porter, Duncan ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d MOSAIQUES DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN B; COMPLEMENT COMPONENT C3; FIBRINOGEN; GELSOLIN; PEPTIDE; PROTEINASE; PROTEOME; TAMM HORSFALL GLYCOPROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CAPILLARY ELECTROPHORESIS; CLASSIFICATION ALGORITHM; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE ANALYSIS; PILOT STUDY; PROTEIN METABOLISM; PROTEIN URINE LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; URINARY EXCRETION; AGED; URINE; YOUNG ADULT;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COMPLEMENT C3; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDES; YOUNG ADULT;

EID: 84923790874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104625     Document Type: Article

References (44)

1. Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43: 22-29. (Pubitemid 30368209)
2. O'Dell JR (2002) Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 46: 283-285.
3. Symmons DP, Jones MA, Scott DL, Prior P (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. The Journal of Rheumatology 25: 1072-1077. (Pubitemid 28350878)
4. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases 69: 1580-1588.
5. Cader MZ, Filer A, Hazlehurst J, de Pablo P, Buckley CD et al. (2011) Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 70: 949-955.
6. Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A et al. (2010) Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 152: W155-W166.
7. Chandra PE, Sokolove J, Hipp BG, Lindstrom TM, Elder JT et al. (2011) Novel multiplex technology for diagnostic characterization of rheumatoid arthritis. Arthritis Res Ther 13: R102.
8. De Franceschi L, Bosello S, Scambi C, Biasi D, De Santis M et al. (2011) Proteome analysis of biological fluids from autoimmune-rheumatological disorders. Proteomics Clin Appl 5: 78-89.
9. Kriegsmann M, Seeley EH, Schwarting A, Kriegsmann J, Otto M et al. (2012) MALDI MS imaging as a powerful tool for investigating synovial tissue. Scand J Rheumatol 41: 305-309.
10. Wild N, Karl J, Grunert VP, Schmitt RI, Garczarek U et al. (2008) Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers. Biomarkers 13: 88-105.
11. Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G et al. (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9: 2424-2437.
12. Metzger J, Kirsch T, Schiffer E, Ulger P, Mentes E et al. (2010) Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int 78: 1252-1262.
13. Dawson J, Walters M, Delles C, Mischak H, Mullen W (2012) Urinary proteomics to support diagnosis of stroke. PLoS One 7: e35879.
14. Delles C, Schiffer E, von Zur Muhlen C, Peter K, Rossing P et al. (2010) Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens 28: 2316-2322.
15. Mischak H, Schanstra JP (2011) CE-MS in biomarker discovery, validation, and clinical application. Proteomics - Clinical Applications 5: 9-23.
16. Mischak H, Kolch W, Aivaliotis M, Bouyssié D, Court M et al. (2010) Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics - Clinical Applications 4: 464-478.
17. Mischak H, Rossing P (2010) Proteomic biomarkers in diabetic nephropathy-reality or future promise? Nephrology Dialysis Transplantation 25: 2843-2845.
18. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48.
19. Carty DM, Siwy J, Brennand JE, Zurbig P, Mullen W et al. (2011) Urinary proteomics for prediction of preeclampsia. Hypertension 57: 561-569.
20. Mischak H, Vlahou A, Ioannidis JP (2013) Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem 46: 432-443.
21. Wittke S, Fliser D, Haubitz M, Bartel S, Krebs R et al. (2003) Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. Journal of Chromatography A 1013: 173-181. (Pubitemid 37297584)
22. Jantos-Siwy J, Schiffer E, Brand K, Schumann G, Rossing K et al. (2009) Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 8: 268-281.
23. Dakna M, Harris K, Kalousis A, Carpentier S, Kolch W et al. (2010) Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics 11.
24. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 57: 289-300.
25. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biology 5: R80. 10.1186/gb-2004-5-10-r80.
26. Karatzoglou A, Smola A, Hornik K, Zeileis A (2004) kernlab - An S4 Package for Kernel Methods in R. Journal of Statistical Software 11: 1-20. (Pubitemid 40068148)
27. Klein J, Eales J, Zürbig P, Vlahou A, Mischak H et al. (2013) Proteasix: A tool for automated and large-scale prediction of proteases involved in naturally occurring peptide generation. Proteomics 13: 1077-1082.
28. Fransen J, van Riel PLCM (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23: S93-S99. (Pubitemid 46657516)
29. Schiffer E, Bick C, Grizelj B, Pietzker S, SchÂfer W (2012) Urinary proteome analysis for prostate cancer diagnosis: Cost-effective application in routine clinical practice in Germany. International Journal of Urology 19: 118-125.
30. Mullan RH, Matthews C, Bresnihan B, FitzGerald O, King L et al. (2007) Early changes in serum type ii collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis & Rheumatism 56: 2919-2928. (Pubitemid 47502738)
31. Verstappen SMM, Poole AR, Ionescu M, King LE, Abrahamowicz M et al. (2006) Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. Arthritis Research & Therapy 8: R31. 10.1186/ar1882.
32. Osborn T, Verdrengh M, Stossel T, Tarkowski A, Bokarewa M (2008) Decreased levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Research & Therapy 10: R117. 10.1186/ar2520.
33. Zhao X, Okeke N, Sharpe O, Batliwalla F, Lee A et al. (2008) Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Research & Therapy 10: R94. 10.1186/ar2478.
34. Isordia-Salas I, Pixley RA, Sainz IM, Martinez-Murillo C, Colman RW (2004) The role of plasma high molecular weight kininogen in experimental intestinal and systemic inflammation. Archives of Medical Research 35: 369-377. (Pubitemid 40018176)
35. Rahman MM, Bhoola KD, Elson CJ, Lemon M, Dieppe PA (1995) Identification and functional importance of plasma kallikrein in the synovial fluids of patients with rheumatoid, psoriatic, and osteoarthritis. Annals of the Rheumatic Diseases 54: 345-350.
36. Williams RJ, Henderson LM, Naidoo Y, Cassim B, Elson CJ et al. (1997) Immunocytochemical analysis of tissue kallikrein and the kinin moiety in rheumatoid synovial fluid neutrophils. Rheumatology 36: 420-425.
37. Cassim B, Shaw OM, Mazur M, Misso NL, Naran A et al. (2009) Kallikreins, kininogens and kinin receptors on circulating and synovial fluid neutrophils: role in kinin generation in rheumatoid arthritis. Rheumatology 48: 490-496.
38. Rahman MM, Lemon MJC, Elson CJ, Dieppe PA, Bhoola KD (1994) Proinflammatory role of tissue kallikrein in modulating pain in inflamed joints. British Journal of Rheumatology 34: 88-90.
39. Eissa A, Cretu D, Soosaipillai A, Thavaneswaran A, Pellett F et al. (2013) Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. Clin Chem Lab Med 51: 317-325.
40. Scarisbrick IA, Epstein B, Cloud BA, Yoon H, Wu J et al. (2011) Functional role of kallikrein 6 in regulating immune cell survival. PLoS One 6: e18376. doi:10.1371/journal.pone.0018376.
41. Judex MO, Mueller BM (2005) Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 166: 645-647. (Pubitemid 40315621)
42. Vincenti M, Brinckerhoff C (2002) Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res 4: 157-164. 10.1186/ar401. (Pubitemid 34460754)
43. Trabandt A, Gay RE, Fassbender HG, Gay S (1991) Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 34: 1444-1451.
44. Green MJ, Gough AKS, Devlin J, Smith J, Astin P et al. (2003) Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 42: 83-88. (Pubitemid 36131572)